You are here

Fabry disease

Sangamo slashes time to market for Fabry gene therapy as FDA agrees to accelerated approval package

Fierce Biotech

Wed, 10/23/24 - 11:33 am

Sangamo Therapeutics

AceLink reports data from Phase I trial of Fabry disease therapy

Clinical Trials Arena

Tue, 02/27/24 - 10:21 am

AceLink Therapeutics

clinical trials

Fabrazyme litigation back in play for Sanofi's Genzyme as appeals court overturns dismissal of 2020 lawsuit

Fierce Pharma

Tue, 02/20/24 - 05:52 pm

New treatment for Fabry disease receives key recommendation

Biopharma Reporter

Tue, 09/12/23 - 10:35 am

Chiesi Fabry disease treatment gets EU marketing authorization

Labiotech.eu

Wed, 05/10/23 - 10:06 am

Protalix BioTherapeutics

ESGCT 2022 – Sangamo strengthens its case in Fabry

EP Vantage

Thu, 10/13/22 - 09:11 am

Sangamo BioSciences

Sangamo presses ahead with Fabry disease gene therapy

BioPharma Dive

Thu, 09/1/22 - 07:50 pm

Sangamo BioSciences

clinical trials

In five patients, Sangamo’s Fabry disease gene therapy appears to be working so far

Endpoints

Tue, 08/30/22 - 06:08 pm

Protalix eyes Fabry drug resubmission thanks to multiple phase 3 readouts

Fierce Biotech

Sun, 03/20/22 - 11:05 pm

Protalix BioTherapeutics

clinical trials

Avrobio halts PhII study for Fabry disease in another setback, shuttering lead program

Endpoints

Tue, 01/4/22 - 10:49 am

clinical trials

Sangamo's Fabry gene therapy clears early clinical test, firing starting gun on preparations for phase 3

Fierce Biotech

Thu, 11/4/21 - 10:48 am

Sangamo Therapeutics

clinical trials

Late-stage letdown for lucerastat dents Idorsia stock

Pharma Letter

Mon, 10/11/21 - 10:20 am

clinical trials

Gene therapy for Fabry: early stages, promising results

BioPharma Dive

Thu, 07/22/21 - 10:02 pm

Freeline Therapeutics

Sangamo Therapeutics

Protalix to propose virtual inspection to clear barrier to FDA approval

Biopharma Reporter

Thu, 05/20/21 - 11:10 am

Protalix BioTherapeutics

Chiesi Farmaceutica

Biotech Avrobio plans head-to-head Fabrazyme trial after FDA changes path to market

Fierce Biotech

Mon, 05/3/21 - 10:59 am

gene therapy R&D

Switch data back Chiesi/Protalix long-acting Fabry drug

Pharmaforum

Thu, 02/25/21 - 10:01 am

A gene therapy pipeline takes shape for a cluster of rare diseases

BioPharma Dive

Mon, 02/15/21 - 11:43 pm

Avrobio gene therapy eliminates toxic substrate in Fabry patient

Fierce Biotech

Mon, 02/8/21 - 10:26 am

clinical trials

Protalix's Fabry Disease Treatment Hits the Mark in Phase III Switch-Over Study

BioSpace

Thu, 12/31/20 - 12:01 pm

Protalix BioTherapeutics

clinical trials

Biotech Protalix, Chiesi edge close to potential Fabry disease approval

Fierce Biotech

Thu, 05/28/20 - 10:53 am

Protalix BioTherapeutics

pegunigalsidase alfa

Pages